Psychedelics have gone from counterculture to cutting-edge medicine.

In this episode of On-Ramp, I sit down with neuroscientist and psychedelic medicine researcher Dr Berra Yazar-Klosinski to explore why compounds like MDMA, psilocybin and ketamine are being re-evaluated by scientists, clinicians and regulators around the world.

Once dismissed as dangerous recreational drugs, these compounds are now showing promise in treating conditions such as PTSD, treatment-resistant depression and anxiety. We unpack the science behind the psychedelic renaissance, why these therapies were prohibited for decades, and what modern neuroscience is revealing about the brain’s remarkable capacity to heal.

We also dive into Dr Berra’s latest research on the epigenetic effects of ketamine and MDMA, exploring how these emerging psychoplastogens may promote lasting changes in the brain beyond the immediate therapeutic experience.

In this episode, we discuss:

• Why psychedelics were banned and why attitudes are changing
• The science behind psychedelic-assisted therapy
• How psychedelics may promote neuroplasticity
• The role of consciousness and interoception in mental health
• The latest clinical evidence for PTSD and depression
• Australia’s leadership in psychedelic medicine
• What the future holds for one of the most exciting frontiers in healthcare

Whether you’re interested in neuroscience, mental health, biotechnology or the future of medicine, this conversation offers a balanced, evidence-based look at one of the fastest-evolving fields in healthcare.

If you enjoyed this episode, please like, subscribe and share it with someone who’d find it interesting.

#Psychedelics #MentalHealth #Neuroscience #MDMA #Psilocybin #Ketamine #Psychiatry #Healthcare #Innovation #OnRampPodcast

Most founders overlook non-dilutive funding, or don’t use it effectively.

In this episode, I sit down with Stuart Haines from Haines Consulting Group to break down the major grant programs available in Australia right now, how to actually structure them into your funding strategy, and where most startups go wrong when applying.

We also cover:

* The biggest grant opportunities founders should be looking at
* How to think about grants vs equity funding
* Common mistakes that kill applications
* What “grant-ready” actually looks like
* Stuart’s journey building a business in this space

If you’re building in Australia, this is a practical guide to using grants as a tool, not a crutch.

In this episode of On-Ramp, we sit down with Niv Dagan, founder and Executive Director of Peak Asset Management.

Niv has built Peak into one of Australia’s most active and well-connected investment and corporate advisory firms, working across capital markets, wealth management, and high-growth companies.

We cover:

* The key investment trends shaping markets right now
* How Niv built Peak from the ground up
* His biggest wins (and painful losses) in the market
* What separates great founders from the rest
* Lessons learned from years in entrepreneurship and investing

This is a candid conversation on risk, resilience, and what it actually takes to succeed in markets where most people get it wrong.

If you’re an investor, founder, or just trying to better understand how smart money thinks, this episode is for you.

Subscribe for more conversations with leading investors, founders, and operators.